In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Lipid droplets and cellular lipid metabolism
Is Glutamine a dangerous supplement
Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make
L-carnitine, recognized for its over-the-counter availability, showcases potential in addressing obesity, diabetes, and lipid-related issues
